ArticleInternational journal of molecular sciences2026
A Novel Epigenetic Mechanism of Intestinal NHE3 Gene Regulation by Histone Acetylation.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
NHE3 is an essential Na+ transporter in the intestine, contributing to diarrhea associated with inflammatory bowel disease (IBD) or intestinal infections. Nevertheless, the influence of histone acetylation on intestinal NHE3 gene expression has not yet been investigated. Various methods were employed, including human intestinal epithelial cells (Caco2 cells), ex vivo mouse and human ileal enteroids, and in vivo mouse models, along with techniques such as real-time qPCR, Western blot, immunofluorescence staining, ChIP, and H3K27Ac HiChIP sequencing analyses. Our findings indicated that valproic acid (VPA, a class I HDAC inhibitor) significantly elevated both NHE3 mRNA and protein levels in IECs. ChIP and Chromatin accessibility assays revealed an enhanced enrichment of acetylated histones (H3/H4) and a more open chromatin state at the p-1329/p-541 region of the NHE3 promoter in Caco2 cells treated with VPA. HDAC2/3 inhibition by MI192 in Caco2 cells and mouse/human ileal organoids or siRNA knockdown of HDAC2 in Caco2 cells significantly increased NHE3 expression. Activation or ectopic overexpression of histone acetylase p300 in Caco2 cells increased NHE3 mRNA expression and enhanced accumulation of acetylated histone (H3) within the p-1329 to -161 bp region of the NHE3 promoter. Additionally, in vivo experiments revealed that VPA significantly increased NHE3 mRNA levels in the ileum and proximal colon of mice, along with increased NHE3 immunostaining. H3K27Ac HiChIP sequencing analysis of isolated IECs from the mouse ileum indicated that VPA increased H3K27Ac acetylation and facilitated chromatin looping between distal enhancers and the NHE3 promoter, thereby stimulating NHE3 transcription. In conclusion, HDAC2 inhibition and histone acetylation play pivotal roles in upregulating NHE3 expression, with therapeutic implications for inflammation-associated diarrhea linked to reduced NHE3 expression/function.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.